cabaletta bio, inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered t cell therapies for patients with b cell-mediated autoimmune diseases. its proprietary technology utilizes chimeric autoantibody receptor (caar) t cells that are designed to selectively bind and eliminate b cells, which produce disease-causing autoantibodies or pathogenic b cells. the company's lead product candidate is dsg3-caart, which is in phase i clinical trial for the treatment of mucosal pemphigus vulgaris, an autoimmune blistering skin disease, and hemophilia a with factor viii alloantibodies. its product candidate pipeline also include musk-caart, a preclinical stage product to treat a subset of patients with myasthenia gravis; fviii-caart, a discovery stage product to treat a subset of patients with hemophilia a; and dsg3/1-caart, a discovery stage product for the treatment of mucocutaneous pemphigus vulgaris. cabaletta bio, inc. has a collaboration with the un
Company profile
Ticker
CABA
Exchange
Website
CEO
Steven Nichtberger
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
CABA stock data
Latest filings (excl ownership)
S-3ASR
Automatic shelf registration
21 Mar 24
S-8
Registration of securities for employees
21 Mar 24
10-K
2023 FY
Annual report
21 Mar 24
8-K
Cabaletta Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
21 Mar 24
8-K
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Systemic Sclerosis
20 Mar 24
8-K
Cabaletta Bio Announces FDA Granted Orphan Drug Designation to CABA-201 for Treatment of Myositis
1 Feb 24
8-K
Results of Operations and Financial Condition
8 Jan 24
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
Cabaletta Bio Reports Third Quarter 2023 Financial Results and Provides Business Update
9 Nov 23
8-K
Cabaletta Bio Receives FDA Clearance of CABA-201 IND Application for Treatment of Generalized Myasthenia Gravis
6 Nov 23
Latest ownership filings
4
Michael Gerard
4 Mar 24
4
David J. Chang
4 Mar 24
4
Steven Nichtberger
4 Mar 24
4
Anup Marda
4 Mar 24
4
Arun Das
4 Mar 24
4
Gwendolyn Binder
4 Mar 24
SC 13G/A
Venrock Healthcare Capital Partners III, L.P.
14 Feb 24
SC 13G/A
BAKER BROS. ADVISORS LP
14 Feb 24
SC 13G/A
ALGER ASSOCIATES INC
14 Feb 24
SC 13G/A
COMMODORE CAPITAL LP
14 Feb 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 115.50 mm | 115.50 mm | 115.50 mm | 115.50 mm | 115.50 mm | 115.50 mm |
Cash burn (monthly) | 4.19 mm | (no burn) | 6.22 mm | 5.65 mm | 4.20 mm | 4.10 mm |
Cash used (since last report) | 27.95 mm | n/a | 41.51 mm | 37.70 mm | 28.03 mm | 27.37 mm |
Cash remaining | 87.55 mm | n/a | 73.99 mm | 77.80 mm | 87.47 mm | 88.13 mm |
Runway (months of cash) | 20.9 | n/a | 11.9 | 13.8 | 20.8 | 21.5 |
Institutional ownership, Q2 2023
97.4% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 89 |
Opened positions | 31 |
Closed positions | 14 |
Increased positions | 30 |
Reduced positions | 12 |
13F shares | Current |
---|---|
Total value | 469.24 bn |
Total shares | 46.98 mm |
Total puts | 36.00 k |
Total calls | 97.40 k |
Total put/call ratio | 0.4 |
Largest owners | Shares | Value |
---|---|---|
Fred Alger Management | 4.57 mm | $59.04 bn |
Alger Associates | 3.48 mm | $42.40 mm |
Adage Capital Partners GP, L.L.C. | 3.27 mm | $42.17 bn |
Commodore Capital | 2.37 mm | $30.57 bn |
Deerfield Management | 2.34 mm | $30.21 bn |
Flynn James E | 2.34 mm | $26.42 mm |
Cormorant Asset Management | 2.22 mm | $28.68 bn |
Lynx1 Capital Management | 2.18 mm | $28.16 bn |
Bain Capital Life Sciences Investors | 2.00 mm | $25.82 bn |
Bain Capital Life Sciences Opportunities III | 2.00 mm | $22.58 mm |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
1 Mar 24 | Michael Gerard | Stock Option Common Stock | Grant | Acquire A | No | No | 23.97 | 100,000 | 2.40 mm | 100,000 |
1 Mar 24 | David J. Chang | Stock Option Common Stock | Grant | Acquire A | No | No | 23.97 | 130,000 | 3.12 mm | 130,000 |
1 Mar 24 | Steven Nichtberger | Stock Option Common Stock | Grant | Acquire A | No | No | 23.97 | 353,000 | 8.46 mm | 353,000 |
1 Mar 24 | Anup Marda | Stock Option Common Stock | Grant | Acquire A | No | No | 23.97 | 130,000 | 3.12 mm | 130,000 |
1 Mar 24 | Arun Das | Stock Option Common Stock | Grant | Acquire A | No | No | 23.97 | 100,000 | 2.40 mm | 100,000 |
News
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
5 Apr 24
Citigroup Maintains Buy on Cabaletta Bio, Raises Price Target to $30
4 Apr 24
Cabaletta Bio Issued ID#NCT06328777 For Phase 1/2 Open-Label Study To Evaluate The Safety And Efficacy Of CABA-201, A CD19-CAR T Cell Therapy, In Subjects With Systemic Sclerosis Posted To Clinical Trials Website On 2024-03-25; Study Is Not Yet Recruiting
25 Mar 24
Cantor Fitzgerald Reiterates Overweight on Cabaletta Bio, Maintains $50 Price Target
22 Mar 24
Wells Fargo Maintains Overweight on Cabaletta Bio, Raises Price Target to $35
22 Mar 24